Previous Close | 4.1600 |
Open | 4.2600 |
Bid | 0.0000 x 2900 |
Ask | 0.0000 x 900 |
Day's Range | 4.0300 - 4.2600 |
52 Week Range | 2.8000 - 16.7700 |
Volume | |
Avg. Volume | 79,785 |
Market Cap | 86.386M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.8820 |
Earnings Date | May 14, 2021 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 15.50 |
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
-- Full results published in European Heart Journal Open -- -- Study met primary safety endpoint -- -- All patients alive, transplant-free, and maintained expected rate of growth one year after treatment -- -- Data supports ongoing clinical development of Lomecel-BTM for HLHS, currently being evaluated in a Phase 2a trial -- MIAMI, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines
– Expects to enroll first patient in Phase 2 clinical trial of Lomecel-B™ for Aging-Related Frailty in Japan in 1Q23 – – Extended cash runway into 2H24 – MIAMI, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today provided a corporate update highlighting the Company’s strategic priorities and anticipated milestones for 2023. “This past year Longeveron m